Serum Progesterone is Negatively Associated with Hypertension and
                    Blood Pressure Indicators Among Men and Postmenopausal Women

Jiayu Shi; Dandan Wei; Lulu Wang; Qingqing Xu; Juan Wang; Cuicui Ma; Jintian Geng; Mengzhen Zhao; Wenqian Huo; Li Linlin; Chongjian Wang; Caini Fan; Zhenxing Mao

doi:10.1055/a-2024-0708

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2023; 55(04): 273-283
DOI: 10.1055/a-2024-0708

Original Article: Endocrine Care

Serum Progesterone is Negatively Associated with Hypertension and Blood Pressure Indicators Among Men and Postmenopausal Women

Jiayu Shi^#

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Dandan Wei^#

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Lulu Wang

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Qingqing Xu

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Juan Wang

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Cuicui Ma

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Jintian Geng

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Mengzhen Zhao

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Wenqian Huo

²Department of Occupational and Environmental Health Sciences, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Li Linlin

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Chongjian Wang

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

,

Caini Fan

³Department of Hypertension, Henan Provincial People’s Hospital, Zhengzhou, China

,

Zhenxing Mao

¹Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, China

› Institutsangaben

Abstract

Sex hormones have been shown to be negatively associated with hypertension, but the relationship between serum progesterone levels and hypertension has not been adequately studied. Therefore, we aimed to evaluate the association between progesterone and hypertension among Chinese rural adults. A total of 6222 participants were recruited, which included 2577 men and 3645 women. The concentration of serum progesterone was detected by liquid chromatography-mass spectrometer system (LC-MS/MS). Logistic regression and linear regression were used to assess the associations between progesterone levels and hypertension and blood pressure related indicators, respectively. Constrained splines were used to fit the dose-response relationships of progesterone with hypertension and blood pressure related indicators. Moreover, the interactive effects of several lifestyle factors and progesterone were identified by a generalized linear model. After fully adjusting the variables, progesterone levels were inversely associated with hypertension in men [odds ratio (OR): 0.851, 95% confidence interval (CI): 0.752, 0.964]. Among men, a 2.738 ng/ml increase in progesterone was associated with a 0.557 mmHg decrease in diastolic blood pressure (DBP) (95% CI: –1.007, –0.107) and a 0.541 mmHg decrease in mean arterial pressure (MAP) (95% CI: –1.049, –0.034), respectively. Similar results were observed in postmenopausal women. Interactive effect analysis showed that only a significant interaction was observed between progesterone and educational attainment on hypertension in premenopausal women (p=0.024). Elevated levels of serum progesterone were associated with hypertension in men. Except for premenopausal women, a negative association of progesterone with blood pressure related indicators was observed.

Key words

progesterone - hypertension - blood pressure - cohort

Volltext

Referenzen

References
1 Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1736-1788
2 World Health Statistics 2021: A visual summary https://www.who.int/data/stories/world-health-statistics-2021-a-visual-summary
3 Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol 2020; 16: 223-237
4 Yusuf S, Joseph P, Rangarajan S. et al. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet 2020; 395: 795-808
5 Mills KT, Bundy JD, Kelly TN. et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441-450
6 Anonymous Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389: 37-55
7 Zhang M, Wu J, Zhang X. et al. Prevalence and control of hypertension in adults in China, 2018. Zhonghua Liu Xing Bing Xue Za Zhi 2021; 42: 1780-1789
8 Lu J, Lu Y, Wang X. et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; 390: 2549-2558
9 Anonymous Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1223-1249
10 Anonymous Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923-1994
11 Petrelli F, Ghidini A, Cabiddu M. et al. Effects of hypertension on cancer survival: a meta-analysis. Eur J Clin Invest 2021; 51: e13493
12 Pickar JH. Progesterone. Climacteric 2018; 21: 305
13 Horwitz KB, Sartorius CA. 90 Years of progesterone: progesterone and progesterone receptors in breast cancer: past, present, future. J Mol Endocrinol 2020; 65: T49-T63
14 Nagy B, Szekeres-Barthó J, Kovács GL. et al. Key to life: physiological role and clinical implications of progesterone. Int J Mol Sci 2021; 22: 11039
15 Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand 2015; 94: 8-16
16 Fedotcheva TA. Clinical use of progestins and their mechanisms of action: present and future (Review). Sovrem Tekhnologii Med 2021; 13: 93-106
17 Piette P. The history of natural progesterone, the never-ending story. Climacteric 2018; 21: 308-314
18 Grimm SL, Hartig SM, Edwards DP. Progesterone receptor signaling mechanisms. J Mol Biol 2016; 428: 3831-349
19 Henderson VW. Progesterone and human cognition. Climacteric 2018; 21: 333-340
20 Anonymous Estradiol/progesterone (Bijuva) for menopausal vasomotor symptoms. Med Lett Drugs Ther 2019; 61: 99-101
21 Prior JC. Progesterone for treatment of symptomatic menopausal women. Climacteric 2018; 21: 358-365
22 Liu X, Mao Z, Li Y. et al. Cohort profile: the Henan rural cohort: a prospective study of chronic non-communicable diseases. Int J Epidemiol 2019; 48: 1756-1756j
23 Fan M, Lyu J, He P. Chinese guidelines for data processing and analysis concerning the International Physical Activity Questionnaire. Zhonghua Liu Xing Bing Xue Za Zhi 2014; 35: 961-964
24 Unger T, Borghi C, Charchar F. et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension 2020; 75: 1334-1357
25 Mofid B, Soltani Z, Khaksari M. et al. What are the progesterone-induced changes of the outcome and the serum markers of injury, oxidant activity and inflammation in diffuse axonal injury patients?. Int Immunopharmacol 2016; 32: 103-110
26 Blacher J, Kretz S, Sorbets E. et al. Epidemiology of hypertension: Differences between women and men. Presse Med 2019; 48: 1240-1243
27 Deer E, Jones J, Cornelius DC et al. Progesterone induced blocking factor reduces hypertension and placental mitochondrial dysfunction in response to sFlt-1 during pregnancy. Cells 2021; 10_ 2817
28 Pecins-Thompson M, Keller-Wood M. Effects of progesterone on blood pressure, plasma volume, and responses to hypotension. Am J Physiol 1997; 272: R377-R385
29 Staessen J, Bulpitt CJ, Fagard R. et al. The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: 427-433
30 Tollan A, Oian P, Kjeldsen SE. et al. Progesterone reduces sympathetic tone without changing blood pressure or fluid balance in men. Gynecol Obstet Invest 1993; 36: 234-238
31 Boschitsch E, Mayerhofer S, Magometschnigg D. Hypertension in women: the role of progesterone and aldosterone. Climacteric 2010; 13: 307-313
32 Dubey RK, Oparil S, Imthurn B. et al. Sex hormones and hypertension. Cardiovasc Res 2002; 53: 688-708
33 Pimenta E. Hypertension in women. Hypertens Res 2012; 35: 148-152
34 Cifkova R, Pitha J, Lejskova M. et al. Blood pressure around the menopause: a population study. J Hypertens 2008; 26: 1976-1982
35 Glisic M, Shahzad S, Tsoli S. et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 2018; 25: 1042-1052
36 Kim JM, Kim TH, Lee HH. et al. Postmenopausal hypertension and sodium sensitivity. J Menopausal Med 2014; 20: 1-6
37 Baker ME, Katsu Y. Progesterone: an enigmatic ligand for the mineralocorticoid receptor. Biochem Pharmacol 2020; 177: 113976
38 Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev 2016; 68: 49-75
39 Cottrell JN, Witcher AC, Comley K. et al. Progesterone-induced blocking factor improves blood pressure, inflammation, and pup weight in response to reduced uterine perfusion pressure (RUPP). Am J Physiol Regul Integr Comp Physiol 2021; 320: R719-R727
40 Dos Santos RL, Da Silva FB, Ribeiro RF. et al. Sex hormones in the cardiovascular system. Horm Mol Biol Clin Investig 2014; 18: 89-103
41 Bejan-Angoulvant T, Arnal JF. Endogenous and exogenous estrogens. Presse Med 2019; 48: 1244-1248
42 Graff-Iversen S, Thelle DS, Hammar N. Serum lipids, blood pressure and body weight around the age of the menopause. Eur J Cardiovasc Prev Rehabil 2008; 15: 83-88
43 Dugravot A, Fayosse A, Dumurgier J. et al. Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study. Lancet Public Health 2020; 5: e42-e50
44 Nordahl H, Hvidtfeldt UA, Diderichsen F. et al. Cohort profile: the social inequality in cancer (SIC) cohort study. Int J Epidemiol 2014; 43: 1750-1758
45 Sun K, Lin D, Li M. et al. Association of education levels with the risk of hypertension and hypertension control: a nationwide cohort study in Chinese adults. J Epidemiol Community Health 2022; 76: 451-457
46 Lopez-Lopez JP, Cohen DD, Alarcon-Ariza N. et al. Ethnic differences in the prevalence of hypertension in Colombia: association with education level. Am J Hypertens 2022; 35: 610-618

Zusatzmaterial

Supplementary Material